Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01951326 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease
A Phase 3 study, sponsored by RedHill Biopharma Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 331
- Enrollment target
NCT01951326: Completed Phase 3 study, sponsored by RedHill Biopharma Limited.
NCT01951326 is a Phase 3 study that has completed, run by RedHill Biopharma Limited. The registered enrollment target is 331 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01951326, a Phase 3 study, has completed, sponsored by RedHill Biopharma Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 331 participants
- Enrollment target
Study Summary
The investigators hypothesize that RHB-104 will have greater efficacy than placebo in Crohn's disease.
Primary Outcome
Reduction of the total Crohn's Disease Activity Index (CDAI) score to less than 150. Lower CDAI scores indicate a better outcome.
Interventions
- DRUG Placebo
- DRUG RHB-104
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 331 participants |
| Start Date | 2013-09 |
| Est. Completion | 2019-08 |
| Phase | Phase 3 |
What the finished NCT01951326 record still lists
NCT01951326 is an interventional study that assigns participants to a tested intervention. The registered 331 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01951326 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01951326 about?
NCT01951326 is a clinical study titled "Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease". The investigators hypothesize that RHB-104 will have greater efficacy than placebo in Crohn's disease.
What is the current status of trial NCT01951326?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 331 participants. The study started on 2013-09. Estimated completion is 2019-08.
What interventions are being tested in trial NCT01951326?
The interventions under investigation include: Placebo (DRUG), RHB-104 (DRUG).
Who is sponsoring clinical trial NCT01951326?
This trial is sponsored by RedHill Biopharma Limited, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01951326's enrollment target sits among peer trials
331 1066th of 2000 higher than 935 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174121 · 332 participants · Phase 2
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- NCT02605785 · 332 participants · NA
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
- NCT04894006 · 332 participants · NA
Dementia Family Caregiver Study
- NCT05130606 · 332 participants · NA
CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia